ROR1 and neoplasm: Viewed from the perspective of the CSC model, a possible interpretation of this result is that inhibition of ROR1‐signaling by cirmtuzumab, which was confirmed by analysis of patient samples from the study, inhibited the CSC population driving tumor progression.